Research Article
Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection
Table 4
Independent prognostic factors for PFS.
| Characteristics | Head | Body/Tail | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | HR | 95% CI | | HR | 95% CI | | HR | 95% CI | | HR | 95% CI | |
| Age | ≤60 years | Reference | | 0.744 | Reference | | NI | Reference | | 0.986 | Reference | | NI | >60 years | 1.051 | 0.746–1.481 | | | | | 1.006 | 0.516–1.963 | | | | | Gender | Female | Reference | | 0.525 | Reference | | NI | Reference | | 0.537 | Reference | | NI | Male | 1.120 | 0.790–1.587 | | | | | 1.232 | 0.636–2.387 | | | | | WBC | ≤10 | Reference | | 0.011 | Reference | | 0.393 | Reference | | 0.864 | Reference | | NI | >10 | 1.965 | 1.165–3.315 | | 1.855 | 0.450–7.656 | | 1.191 | 0.161–8.825 | | | | | NLR | ≤3.32 | Reference | | 0.335 | Reference | | NI | Reference | | 0.005 | Reference | | 0.015 | >3.32 | 1.184 | 0.840–1.668 | | | | | 3.324 | 1.441–7.669 | | 3.338 | 1.267–8.798 | | dNLR | ≤3.32 | Reference | | 0.815 | Reference | | NI | Reference | | 0.858 | Reference | | NI | >3.32 | 1.045 | 0.723–1.509 | | | | | 0.942 | 0.492–1.804 | | | | | PLR | ≤98.13 | Reference | | 0.05 | Reference | | 0.814 | Reference | | 0.255 | Reference | | NI | >98.13 | 2.272 | 1.001–5.158 | | 1.112 | 0.460–2.685 | | 1.501 | 0.746–3.018 | | | | | PNI | 0 | Reference | | 0.329 | Reference | | NI | Reference | | 0.79 | Reference | | NI | 1 | 1.232 | 0.810–1.872 | | | | | 1.137 | 0.440–2.936 | | | | | SII | ≤1000 | Reference | | 0.837 | Reference | | NI | Reference | | 0.106 | Reference | | NI | >1000 | 1.037 | 0.732–1.468 | | | | | 2.229 | 0.843–5.898 | | | | | mGPS | 0 | Reference | | | Reference | | NI | Reference | | | Reference | | | 1 | 1.122 | 0.895–1.406 | 0.319 | | | | 0.675 | 0.157–2.911 | 0.598 | 1.960 | 0.212–18.154 | 0.553 | 2 | 2.11 | 0.644–1.889 | 0.214 | | | | 3.251 | 0.592–17.861 | 0.175 | 13.645 | 1.175–158.459 | 0.037 | PI | 0 | Reference | | | Reference | | | Reference | | | Reference | | | 1 | 1.346 | 1.038–1.745 | 0.025 | 0.947 | 0.198–4.531 | 0.946 | 0.708 | 0.094–5.308 | 0.737 | 0.230 | 0.010–5.382 | 0.361 | 2 | 1.224 | 0.987–2.114 | 0.066 | 1.496 | 0.327–6.844 | 0.604 | 2.479 | 0.293–21.006 | 0.405 | 0.546 | 0.117–3.574 | 0.257 | ALB (g/L) | ≤35 | Reference | | 0.815 | Reference | | NI | Reference | | 0.74 | Reference | | NI | >35 | 0.949 | 0.614–1.467 | | | | | 0.783 | 0.184–3.329 | | | | | CRP (ng/L) | ≤3 | Reference | | 0.138 | Reference | | NI | Reference | | 0.018 | Reference | | 0.425 | >3 | 1.296 | 0.920–1.825 | | | | | 2.869 | 1.197–6.877 | | 1.579 | 0.849–4.552 | | CA19-9 (U/ml) | ≤35 | Reference | | 0.020 | Reference | | 0.364 | Reference | | 0.086 | Reference | | NI | >35 | 1.762 | 1.094–2.838 | | 0.774 | 0.445–1.346 | | 2.347 | 0.885–6.225 | | | | | CEA (ng/ml) | ≤5 | Reference | | 0.010 | Reference | | 0.007 | Reference | | 0.320 | Reference | | NI | >5 | 1.595 | 1.118–2.274 | | 1.785 | 1.167–2.730 | | 1.392 | 0.725–2.675 | | | | | HBV infection | Absence | Reference | | 0.997 | Reference | | NI | Reference | | 0.331 | Reference | | NI | Presence | 0.999 | 0.507–1.966 | | | | | 2.735 | 0.360–20.747 | | | | | Chemotherapy | No | Reference | | 0.054 | Reference | | 0.001 | Reference | | 0.690 | Reference | | NI | Yes | 1.396 | 0.994–1.961 | | 0.476 | 0.302–0.749 | | 1.141 | 0.594–2.195 | | | | | Hemorrhage | Absence | Reference | | 0.990 | Reference | | NI | Reference | | 0.585 | Reference | | NI | Presence | 1.008 | 0.320–3.170 | | | | | 0.570 | 0.076–4.269 | | | | | Pancreatic fistula | Absence | Reference | | 0.407 | Reference | | NI | Reference | | 0.237 | Reference | | NI | Presence | 1.178 | 0.800–1.733 | | | | | 0.549 | 0.203–1.482 | | | | | Biliary fistula | Absence | Reference | | 0.971 | Reference | | NI | Reference | | 0.873 | Reference | | NI | Presence | 0.991 | 0.627–1.568 | | | | | 1.071 | 0.460–2.495 | | | | | Abdominal infection | Absence | Reference | | 0.313 | Reference | | NI | Reference | | 0.348 | Reference | | NI | Presence | 1.319 | 0.770–2.257 | | | | | 2.641 | 0.348–20.038 | | | | | LN16 | Absence | Reference | | LA | Reference | | 0.123 | Reference | | LA | Reference | | NI | Presence | | | | 1.939 | 0.835–4.503 | | | | | | | | Tumor differentiation | Well | Reference | | LA | Reference | | NI | Reference | | LA | Reference | | NI | Moderate | | | | | | | | | | | | | Poor | | | | | | | | | | | | | Imaging tumor size (cm) | ≤2 | Reference | | LA | Reference | | | Reference | | LA | Reference | | NI | 2–4 | | | | 0.974 | 0.425–2.231 | 0.951 | | | | | | | >4 | | | | 1.703 | 1.195–3.648 | 0.029 | | | | | | | Local progression | Absence | Reference | | LA | Reference | | <0.001 | Reference | | LA | Reference | | NI | Presence | | | | 13.643 | 7.279–25.569 | | | | | | | | Liver-only metastasis | Absence | Reference | | LA | Reference | | <0.001 | Reference | | LA | Reference | | NI | Presence | | | | 18.632 | 10.506–33.043 | | | | | | | | Lung-only metastasis | Absence | Reference | | LA | Reference | | <0.001 | Reference | | LA | Reference | | NI | Presence | | | | 19.313 | 7.054–52.877 | | | | | | | | Local + distant metastasis | Absence | Reference | | LA | Reference | | | Reference | | LA | Reference | | NI | Presence | | | | 13.535 | 5.905–31.024 | <0.001 | | | | | | | Multiple metastases | Absence | Reference | | LA | Reference | | NI | Reference | | LA | Reference | | NI | Presence | | | | 33.96 | 13.137–87.808 | | | | | | | | TNM stage | IA | Reference | | LA | Reference | | | Reference | | LA | Reference | | NI | IB | | | | 1.382 | 0.476–4.009 | 0.552 | | | | | | | IIA | | | | 1.253 | 0.486–3.232 | 0.64 | | | | | | | IIB | | | | 4.401 | 1.537–12.602 | 0.006 | | | | | | | III | | | | 1.776 | 0.734–4.299 | 0.203 | | | | | | | Back membrane invasion | Absence | Reference | | LA | Reference | | 0.09 | Reference | | LA | Reference | | NI | Presence | | | | 1.460 | 0.943–2.262 | | | | | | | | LNR | 0 | Reference | | LA | Reference | | NI | Reference | | LA | Reference | | NI | 0–0.16 | | | | 0.434 | 0.144–1.306 | 0.137 | | | | | | | >0.16 | | | | 1.043 | 0.576–1.886 | 0.890 | | | | | | | Positive LN number | 0 | Reference | | LA | Reference | | | Reference | | LA | Reference | | NI | 1–3 | | | | 0.416 | 0.144–1.203 | 0.106 | | | | | | | >4 | | | | 0.587 | 0.274–1.587 | 0.323 | | | | | | | Pathological size (cm) | ≤2 | Reference | | LA | Reference | | NI | Reference | | LA | Reference | | | 2–4 | | | | | | | | | | 0.099 | 0.016–0.625 | 0.014 | >4 | | | | | | | | | | 0.556 | 0.252–1.227 | 0.146 | Imaging LN size (cm) | ≤0.5 | Reference | | LA | Reference | | NI | Reference | | LA | Reference | | | 0.5–1.5 | | | | | | | | | | 0.254 | 0.086–0.751 | 0.013 | >1.5 | | | | | | | | | | 2.999 | 0.813–11.060 | 0.099 | Imaging vascular invasion | Absence | Reference | | LA | Reference | | NI | Reference | | LA | Reference | | 0.239 | Presence | | | | | | | | | | 1.670 | 0.712–3.919 | |
|
|
NI, not included; LA, Included in LASSO analysis. Abbreviations as in Table 1. |